Search Results - "Plutzky, J."

Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice by Kiefer, F. W., Neschen, S., Pfau, B., Legerer, B., Neuhofer, A., Kahle, M., Hrabé de Angelis, M., Schlederer, M., Mair, M., Kenner, L., Plutzky, J., Zeyda, M., Stulnig, T. M.

“…Aims/hypothesis Obesity is strongly associated with the development of non-alcoholic fatty liver disease (NAFLD). The cytokine osteopontin (OPN) was recently…”
Get full text

A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes by Mitchell, Sharon, Malanda, Belma, Damasceno, Albertino, Eckel, Robert H., Gaita, Dan, Kotseva, Kornelia, Januzzi, James L., Mensah, George, Plutzky, Jorge, Prystupiuk, Maksym, Ryden, Lars, Thierer, Jorge, Virani, Salim S., Sperling, Laurence

“…•The ideal pathway of care for those living with type 2 diabetes to prevent and manage CVD is a key feature of this consensus document. It offers a pathway of…”
Get full text

PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? by Ahmed, W., Ziouzenkova, O., Brown, J., Devchand, P., Francis, S., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F., Plutzky, J.

“… Peroxisome proliferator‐activated receptors (PPARs) as ligand‐activated nuclear receptors involved in the transcriptional regulation of lipid metabolism,…”
Get full text

Discontinuation of Statin in Routine Care Settings: A Cohort Study by Zhang, H, Plutzky, J, Skentzos, S

Get full text

Peroxisome proliferator-activated receptors in endothelial cell biology by Plutzky, J

“…New insights into the endothelium as a dynamic, interactive organ have generated increased interest in endothelial cell transcriptional regulation. Peroxisomal…”
Get full text

Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms by Plutzky, J

“…Peroxisome Proliferator-Activated Receptors (PPARs), members of the steroid hormone nuclear receptor superfamily, act as ligand-activated transcription factors…”
Get full text

Identification of a Human src Homology 2-Containing Protein-Tyrosine-Phosphatase: A Putative Homolog of Drosophila Corkscrew by Freeman, Robert M., Plutzky, Jorge, Neel, Benjamin G.

“…src homology 2 (SH2) domains direct binding to specific phosphotyrosyl proteins. Recently, SH2-containing protein-tyrosine-phosphatases (PTPs) were identified…”
Get full text

Isolation of a src Homology 2-Containing Tyrosine Phosphatase by Plutzky, Jorge, Neel, Benjamin G., Rosenberg, Robert D.

“…Tyrosine phosphorylation is controlled by the opposing actions of tyrosine kinases and phosphotyrosine phosphatases (PTPs). src homology 2 domains (SH2) are…”
Get full text

Liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure within 2 weeks in patients with type 2 diabetes by Fonseca, V, Falahati, A, Zychma, M, Madsbad, S, Plutzky, J

Get full text

Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR–RXR complex by Ziouzenkova, Ouliana, Plutzky, Jorge

“…Retinoids, naturally-occurring vitamin A derivatives, regulate metabolism by activating specific nuclear receptors, including the retinoic acid receptor (RAR)…”
Get full text

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients by Nissen, Steven E., Lincoff, A. Michael, Brennan, Danielle, Ray, Kausik K., Mason, Denise, Kastelein, John J.P., Thompson, Paul D., Libby, Peter, Cho, Leslie, Plutzky, Jorge, Bays, Harold E., Moriarty, Patrick M., Menon, Venu, Grobbee, Diederick E., Louie, Michael J., Chen, Chien-Feng, Li, Na, Bloedon, LeAnne, Robinson, Paula, Horner, Maggie, Sasiela, William J., McCluskey, Jackie, Davey, Deborah, Fajardo-Campos, Pedro, Petrovic, Predrag, Fedacko, Jan, Zmuda, Witold, Lukyanov, Yury, Nicholls, Stephen J.

“…In this randomized trial, statin-intolerant patients with, or at high risk for, CVD received bempedoic acid or placebo. Bempedoic acid reduced LDL cholesterol…”
Get full text

PPARα in atherosclerosis and inflammation by Zandbergen, Fokko, Plutzky, Jorge

“…Peroxisome proliferator-activated receptor (PPAR)α is a nuclear receptor activated by natural ligands such as fatty acids as well as by synthetic ligands such…”
Get full text

Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis by Plutzky, J, Garber, A, Falahati, A, Toft, A.D, Poulter, N.R

Get full text

Inflammatory pathways in atherosclerosis and acute coronary syndromes by Plutzky, Jorge

“…Evidence from a broad range of studies demonstrates that atherosclerosis is a chronic disease that, from its origins to its ultimate complications, involves…”
Get full text

PPARs as Therapeutic Targets: Reverse Cardiology? by Plutzky, Jorge

“…PPARs (peroxisome proliferator-activated receptors) are nuclear receptors which reduces inflammation and atherosclerosis, the buildup in arteries of the…”
Get full text

Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW) by Deanfield, J, Buse, J B, Gerward, S, Kees Hovingh, G, Michael Lincoff, A, Plunde, O, Plutzky, J, Staerk-Ostergaard, J, K Mcguire, D

“…Abstract Introduction Inflammation is a pathophysiological process associated with increased cardiovascular (CV) risk, with high-sensitivity C-reactive protein…”
Get full text

Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial by Colhoun, H, Lincoff, A M, Linder, M, Hardt-Lindberg, S, Hovingh, G K, Kahn, S, Kalayci Oral, T, Lingvay, I, Plutzky, J, Ryan, D H, Weeke, P E, Deanfield, J

“…Abstract Background Glucagon-like peptide 1 (GLP-1) receptor agonists have been shown to reduce major adverse cardiovascular (CV) events (MACE) in people with…”
Get full text

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial by Colhoun, Helen M., Lingvay, Ildiko, Brown, Paul M., Deanfield, John, Brown-Frandsen, Kirstine, Kahn, Steven E., Plutzky, Jorge, Node, Koichi, Parkhomenko, Alexander, Rydén, Lars, Wilding, John P. H., Mann, Johannes F. E., Tuttle, Katherine R., Idorn, Thomas, Rathor, Naveen, Lincoff, A. Michael

“…The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide ( n  = 8,803) versus placebo ( n  = 8,801) in…”
Get full text

The vascular biology of atherosclerosis by Plutzky, Jorge

“…Despite many advances in cardiology, atherosclerosis remains a major medical problem. This is especially the case for individuals with insulin resistance and…”
Get more information

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT by Lingvay, Ildiko, Deanfield, John, Kahn, Steven E, Weeke, Peter E, Toplak, Hermann, Scirica, Benjamin M, Rydén, Lars, Rathor, Naveen, Plutzky, Jorge, Morales, Cristobal, Lincoff, A Michael, Lehrke, Michael, Jeppesen, Ole Kleist, Gajos, Grzegorz, Colhoun, Helen M, Cariou, Bertrand, Ryan, Donna

“…To evaluate the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide…”
Get full text